ALVOTECH SA (ALVO) Stock Price, Forecast & Analysis
NASDAQ:ALVO • LU2458332611
ALVO Key Statistics, Chart & Performance
The current stock price of ALVO is 4.64 USD. In the past month the price decreased by -6.26%. In the past year, price decreased by -64.28%.
ALVO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALVO. When comparing the yearly performance of all stocks, ALVO is a bad performer in the overall market: 91.58% of all stocks are doing better.
ALVO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALVO. While ALVO is still in line with the averages on profitability rating, there are concerns on its financial health.
ALVO Financial Highlights
Over the last trailing twelve months ALVO reported a non-GAAP Earnings per Share(EPS) of 0.2. The EPS increased by 122.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.12% | ||
| ROA | 4.93% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALVO Forecast & Estimates
12 analysts have analysed ALVO and the average price target is 8.93 USD. This implies a price increase of 92.35% is expected in the next year compared to the current price of 4.64.
For the next year, analysts expect an EPS growth of 116.02% and a revenue growth 28.26% for ALVO
ALVO Ownership
ALVO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALVO
Company Profile
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Company Info
ALVOTECH SA
9, Rue De Bitbourg
Luxembourg LU
Employees: 1011
Phone: 35244224500
ALVOTECH SA / ALVO FAQ
What does ALVOTECH SA do?
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
What is the stock price of ALVOTECH SA today?
The current stock price of ALVO is 4.64 USD. The price decreased by -1.49% in the last trading session.
What is the dividend status of ALVOTECH SA?
ALVO does not pay a dividend.
What is the ChartMill rating of ALVOTECH SA stock?
ALVO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Should I buy ALVO stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALVO.
What is the employee count for ALVO stock?
ALVOTECH SA (ALVO) currently has 1011 employees.
What is the Short Interest ratio of ALVOTECH SA (ALVO) stock?
The outstanding short interest for ALVOTECH SA (ALVO) is 1.94% of its float.